Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy

Heo, Suyeon; Young, David C.; Safirstein, Julie; Bourque, B.; Antell, Martine H.; DiLoreto, Stefanie E.; Rotolo, Shannon M.

doi:10.1016/j.jcf.2021.10.002

Cited by 54 publications

(39 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our experience identified mood disturbances as one of the most common adverse events associated with ELX/TEZ/IVA therapy. Although no mood disturbances were reported in the randomized control trials, subsequent case series have documented development of mental status changes shortly after ELX/TEZ/IVA initiation, 8 and similar reports exist for earlier generation CFTR modulators 9 . Although the mechanism for these findings is unknown, potential explanations include drug–drug interactions with concurrent psychotropic medications, modification of CFTR in the brain, or merely incidental findings based on increased screening in a population with known higher incidence of mood disorders 9 …”

Section: Discussionmentioning

confidence: 96%

Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients

et al. 2022

View full text Add to dashboard Cite

Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is a highly effective therapy for patients with cystic fibrosis (CF) with potential benefits in lung transplant recipients (LTRs) for extrapulmonary CF manifestations such as sinus disease, gastrointestinal disease, weight loss, and pancreatic insufficiency. Although the primary endpoint of approval studies was pulmonary function, non-pulmonary benefits reported with ELX/TEZ/IVA include weight gain, improvement in sinus disease, and improvements in pancreatic insufficiency,

show abstract

Section: Discussionmentioning

confidence: 96%

Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Insomnia, anxiety, and mental fogginess have been reported. 79 Dose adjustment may be helpful in dealing with these neurocognitive adverse effects. 80 These real-world effects emphasize the importance of a sustained and coordinated approach to CF mental health care now and in the future.…”

Section: Mental Healthmentioning

confidence: 99%

Beyond the Lungs—Emerging Challenges in Adult Cystic Fibrosis Care

Mulrennan

Sapru

Tewkesbury

et al. 2022

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Cystic fibrosis (CF) is a multisystem disease. This article provides an up-to-date review of many of the nonrespiratory complications of CF, including mental health issues, nutritional and gastrointestinal problems, fertility issues, diabetes mellitus, bone health and musculoskeletal problems, liver disease, renal problems, and risk of malignancy. It highlights the recent impact of new therapies, including CF transmembrane conductance regulator modulators, on the nonrespiratory complications of CF and provides insights into the potential challenges faced by an aging population of adults with CF and their caregivers, including the potential future risk for cardiovascular disease.

show abstract

“…Furthermore, cardiovascular complications, obstructive sleep apnea, osteopenia and skeletal fragility are all emerging problems [51] , [52] , [53] , [54] , [55] . Addressing mental health issues and promoting emotional wellness warrant ongoing attention, particularly as those with depression are at increased risk of death [56] , [57] , [58] , [59] , [60] , [61] .…”

Section: Extrapulmonary Complicationsmentioning

confidence: 99%